
Pfizer Gains Access to 23andMe's Genetic Mine
23andMe is betting its growing troves of genetic data will prove essential to drug companies, medical researchers, and even health and wellness companies.
23andMe Inc., the genetic-testing startup backed by
The collaboration with Pfizer is the broadest announced so far in
The agreement unveiled today gives the U.S.’s largest drugmaker access to anonymous, aggregated information from consumers who bought 23andMe’s test over the past seven years to learn about their own genetic histories. It includes only people who agreed to let their data be used in research. Pfizer and 23andMe declined to give the deal’s value.
Reported on Bloomberg:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.